In 2022, the global preimplantation genetic testing market will be worth $527 million. Looking ahead, IMARC Group forecasts the market to reach US$ 883 million by 2028, with a CAGR of 9.1% from 2018 to 2028.
.jpg "The Global Preimplantation Genetic Testing Market 2018-2028 (USD Million)")
Preimplantation genetic testing, combines genetic screening and assisted reproductive technology (ART) to enable parents to screen and diagnose their potential children before implantation for genetic or chromosomal characteristics. The technology has been a godsend to couples with family histories of Preimplantation genetic diagnosis disorders and chromosomal mutations causing infertility. However, expanding its use to permit prospective parents to select embryos based on a wide array of genetic characteristics presents substantial risks to individuals involved in the procedure and to society as a whole. Although preimplantation genetic testing use has remained extremely limited due to technological constraints, expense, and moderate success rates, recent advances in genetic testing procedures will remove many of these obstacles and significantly increase the benefits of its use. Better tests, providing better information, will expand the use of this technology from embryos known to be at risk for serious disease - preimplantation genetic diagnosis - to the testing of all or almost all in vitro embryos for multiple genetic characteristics - preimplantation genetic screening (PGS).
The global preimplantation genetic testing market is categorized based on test type and technology. Based on test type, the aneuploidy held the largest share in 2018, representing the most common indication of preimplantation genetic diagnosis in IVF cycles. By technology, NGS dominated the global preimplantation genetic testing market in 2018.
Regionally, North America accounted for the largest market share of the global preimplantation genetic testing market in 2018, while Asia Pacific is set to grow at a highest CAGR by 2025. Leading players of the global preimplantation genetic testing market include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Inc., Beijing Genomics Institute (BGI), Abbott Laboratories, Natera, Inc., Genea Limited, Rubicon Genomics, Inc. and Oxford Gene Technology among others.
Preimplantation Genetic Testing Market Scope
| Metrics | Details |
| Base Year | 2023 |
| Historic Data | 2018-2022 |
| Forecast Period | 2024-2028 |
| Study Period | 2018-2028 |
| Forecast Unit | Value (USD) |
| Revenue forecast in 2028 | US$ 883 million |
| Growth Rate | CAGR of 9.1 % during 2018-2028 |
| Segment Covered | by Procedure, Type, Technology, Application,Region. |
| Regions Covered | North America, Europe, Asia Pacific, South America, Middle East and Africa |
| Key Players Profiled | Natera, Inc.CooperSurgical, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., IGENOMIX, Reprogenetics, LLC, Genea Limited, PerkinElmer, Inc., Genesis Genetics Ltd., Quest Diagnostics Incorporated, Thermo FisherScientific, Inc, Bioarrayn Genetics, Laboratory Corporation of America Holdings, California Pacific Medical Center and Reproductive Health Science Ltd |
Key Segment Of The Preimplantation Genetic Testing Market
by Procedure (USD Million)
• Preimplantation Genetic Diagnosis (Pgd)
• Preimplantation Genetic Screening (Pgs) Beta Thalassemia
By Type (USD Million)
• Chromosomal Abnormalities
• X Linked Diseases
• Embryo Testing
• Aneuploidy Screening
By Application (USD Million)
• Embryo Hla Typing For Stem Cell Therapy
• Ivf Prognosis
• Late Onset Genetic Disorders
• Inherited Genetic Disease
by Technology (USD Million)
• Next Generation Sequencing
• Polymerase Chain Reaction
• Fluorescence In Situ Hybridization
by End User (USD Million)
• Maternity Centers & Fertility Clinics
• Hospitals
• Diagnostic Labs
Regional Overview (USD Million)
North America
• US
• Canada
Europe
• Germany
• France
• UK
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Rest of Asia Pacific
South America
• Mexico
• Brazil
• Rest of South America
Middle East and South Africa
Frequently Asked Questions (FAQ) :
the preimplantation genetic testing market is growing at a CAGR of 9.1% during the forecast period.
North America dominated the market for preimplantation genetic testing market and accounted for the largest revenue share
The major contenders in the global preimplantation genetic testing market Natera, Inc.CooperSurgical, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., IGENOMIX, Reprogenetics, LLC, Genea Limited, PerkinElmer, Inc., Genesis Genetics Ltd., Quest Diagnostics Incorporated, Thermo FisherScientific, Inc, Bioarrayn Genetics, Laboratory Corporation of America Holdings, California Pacific Medical Center and Reproductive Health Science Ltd.